KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to $30.6 million.

  • Recursion Pharmaceuticals' Treasury Shares rose 6934.6% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.6 million, marking a year-over-year increase of 6934.6%. This contributed to the annual value of $27.3 million for FY2024, which is 7935.27% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Treasury Shares stood at $30.6 million, which was up 6934.6% from $21.7 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Treasury Shares registered a high of $30.6 million during Q3 2025, and its lowest value of $76762.0 during Q2 2021.
  • For the 5-year period, Recursion Pharmaceuticals' Treasury Shares averaged around $13.4 million, with its median value being $15.4 million (2023).
  • Its Treasury Shares has fluctuated over the past 5 years, first skyrocketed by 905572.29% in 2022, then skyrocketed by 211.83% in 2024.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Treasury Shares stood at $478136.0 in 2021, then surged by 1341.96% to $6.9 million in 2022, then skyrocketed by 120.81% to $15.2 million in 2023, then skyrocketed by 79.35% to $27.3 million in 2024, then rose by 12.23% to $30.6 million in 2025.
  • Its last three reported values are $30.6 million in Q3 2025, $21.7 million for Q2 2025, and $26.2 million during Q1 2025.